HFS
LEGN icon

Hantz Financial Services’s Legend Biotech LEGN Stock Holding History

Hantz Financial Services’s Portfolio LEGN Stock Details LEGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$318K Sell
11,009
-2,784
-20% -$75.1K ﹤0.01% 919
2026
Q1 		$250K Buy
13,793
+3,425
+33% +$65.3K ﹤0.01% 909
2025
Q4 		$225K Buy
10,368
+3,217
+45% +$92.2K ﹤0.01% 825
2025
Q3 		$233K Buy
7,151
+5,054
+241% +$187K ﹤0.01% 696
2025
Q2 		$74K Buy
2,097
+1,890
+913% +$61.2K ﹤0.01% 838
2025
Q1 		$7K Buy
+207
New +$7.42K ﹤0.01% 1060

Other funds holding LEGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return

Hantz Financial Services's LEGN Position: Q2 2026 in Review

Hantz Financial Services reduced its Legend Biotech (LEGN) stake by 20% in Q2 2026, selling an estimated $75.1K and leaving 11,009 shares worth $318K. The position accounts for ﹤0.01% of the portfolio, ranked #919.

Hantz Financial Services first reported a position in LEGN in Q1 2025 and has held it in 6 quarters since. 219 funds tracked by Wall St. Rank hold LEGN as of Q2 2026.

  • Hantz Financial Services held 11,009 shares of Legend Biotech worth $318K as of Q2 2026.
  • Hantz Financial Services sold 2,784 Legend Biotech shares in Q2 2026, an estimated $75.1K.
  • Legend Biotech made up ﹤0.01% of Hantz Financial Services's portfolio in Q2 2026, its #919 holding.
  • Hantz Financial Services first reported a position in Legend Biotech in Q1 2025 and has held it in 6 quarters since.
  • 219 funds tracked by Wall St. Rank held Legend Biotech as of Q2 2026.

Based on Hantz Financial Services's 13F filing for Q2 2026, filed 13 Aug 2026.